文献速递妇科

帕博利珠单抗联合或不联合仑伐替尼治疗复发性子宫癌肉瘤的疗效与安全性:一项真实世界单中心研究

Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.
PubMed 文献 · Gynecol Oncol · 2025-12-04

本研究回顾性分析了2018至2025年间单中心43例复发性子宫癌肉瘤患者,其中9例接受帕博利珠单抗单药治疗,34例接受帕博利珠单抗联合仑伐替尼治疗。中位无进展生存期为5个月,总生存期为14个月,客观缓解率37.5%,疾病控制率67.5%。联合治疗较单药显示更长的中位无进展生存期(5个月 vs 3个月)和总生存期(19个月 vs 7个月),但无统计学显著性。

要点

  • 帕博利珠单抗联合或不联合仑伐替尼在复发性子宫癌肉瘤中显示中等疗效,安全性可控。
  • 联合治疗组中位无进展生存期5个月 vs 单药组3个月,中位总生存期19个月 vs 7个月,均无统计学显著性。
  • 最常见不良事件为手足综合征(29.4%)和甲状腺功能减退(26.5%),未观察到治疗相关死亡。

核心结论

  • 帕博利珠单抗联合或不联合仑伐替尼在复发性子宫癌肉瘤中显示出中等疗效且安全性可控,但单药治疗结果因样本量小仍属探索性。
  • 这项真实世界研究支持免疫治疗在部分子宫癌肉瘤患者中的潜在作用,并强调需要前瞻性试验。

研究设计与样本

  • 回顾性分析2018年至2025年间在单中心接受帕博利珠单抗单药治疗(n=9)或联合仑伐替尼治疗(n=34)的43例复发性子宫癌肉瘤患者。
  • 分析临床病理特征、治疗反应、生存结局及按CTCAE v5.0分级的不良事件。

主要发现

  • 中位无进展生存期为5个月,中位总生存期为14个月。
  • 客观缓解率为37.5%,疾病控制率为67.5%。
  • 联合治疗组中位无进展生存期5个月 vs 单药组3个月,中位总生存期19个月 vs 7个月,均无统计学显著性(PFS p=0.99;OS p=0.25)。
  • 探索性多变量分析中,较大肿瘤尺寸与较短无进展生存期(HR 2.73,95%CI 1.18-6.28)和总生存期(HR 5.36,95%CI 1.84-15.63)相关。
  • 最常见不良事件为手足综合征(29.4%)和甲状腺功能减退(26.5%),未观察到治疗相关死亡。

临床怎么用

  • 作者认为,这项真实世界研究支持免疫治疗在部分子宫癌肉瘤患者中的潜在作用,并强调需要前瞻性试验。

局限性

  • 单药治疗结果因样本量小仍属探索性。
  • 原文指出需要前瞻性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare, aggressive endometrial cancer with limited treatment options for recurrence. The role of immunotherapy in UCS remains unclear. This study aimed to evaluate the efficacy and safety of pembrolizumab with or without lenvatinib in recurrent UCS. METHODS: We retrospectively analyzed 43 patients with recurrent UCS treated with pembrolizumab monotherapy (n = 9) or in combination with lenvatinib (n = 34) at a single center between 2018 and 2025. We analyzed clinicopathologic features, treatment response, survival outcomes and adverse events (AEs) graded per the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. RESULTS: Median progression-free survival (PFS) was 5 months and overall survival (OS) was 14 months. Objective response rate (ORR) was 37.5 % and disease control rate (DCR) was 67.5 %. The combination showed longer median PFS (5 vs. 3 months) and OS (19 vs. 7 months) compared with monotherapy, without statistical significance (PFS p = 0.99; OS p = 0.25). In exploratory multivariable analyses, larger tumor size was associated with shorter PFS (HR 2.73, 95 % CI 1.18-6.28) and OS (HR 5.36, 95 % CI 1.84-15.63). The most frequent AEs were hand-foot syndrome (29.4 %) and hypothyroidism (26.5 %), but no treatment-related deaths were observed. CONCLUSIONS: Pembrolizumab with or without lenvatinib demonstrated modest efficacy with a manageable safety profile in recurrent UCS, although monotherapy outcomes remain exploratory due to the small sample size. This real-world study supports the potential role of immunotherapy for select UCS patients and highlights the need for prospective trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lim S, Chung YE, Seo JH, et al. Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study. Gynecol Oncol. 2025. PMID: 41349346. doi:10.1016/j.ygyno.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。